RAPT Therapeutics Inc. (RAPT): Important & Key Factors of Healthcare Stock

H.C. Wainwright announced it was Initiated coverage of RAPT Therapeutics Inc. in a research note on June 01, 2020. Cantor Fitzgerald rated the stock as an Overweight in a research noted published on May 19, 2020. ROTH Capital rated the stock as a Buy in a research note published on April 13, 2020.

Robbins Wendye, the Director of RAPT Therapeutics Inc., bought 500.0 shares at the valuation of $28.70 during an exchange that occurred on Sep 28, which implies that Robbins Wendye is holding 6,550 shares at the estimation of $14,350.

In another transaction, on Sep 24, Director of RAPT Therapeutics Inc., Robbins Wendye, bought 200.0 shares at the price of $28.00. After this activity, Robbins Wendye now keeps 6,050 shares of RAPT Therapeutics Inc., esteemed at $5,600.

RAPT Recent Trade

The share price of RAPT descended by -$0.95 during the exchanging session on 09/29/20 to exchange at $27.42. RAPT Therapeutics Inc. stock has an exchanging volume of 0.44 million shares, which is high, contrasted with its 3-months average volume of 193.48K shares. Its market capitalization has now reached to $658.35M and analysts have a consensus target price of $42.50 in the 12-month period.

RAPT Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, RAPT price has dropped by -18.68%. In the course of past three months sees the stock go down around -5.51%, while it has gain 28.91% over the past six months and -0.69% since the start of the year.

RAPT Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 1.28 billion, which was higher than the gauge of 1M made by certain experts. For that equivalent quarter, RAPT Therapeutics Inc. posted -$0.51 earnings per share (EPS) which was above the consensus estimate of -$0.58 by $0.07, which represents to an expansion by 12.10%.

RAPT Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on RAPT Therapeutics Inc. has seen its stock exchanging -28.37% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +30.14% above its three-month low. A more extensive look sees RAPT exchanging -46.46% beneath its 52-week high and 160.65% above from its 52-week low price.

RAPT Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 9.01%, while it has a month to month instability of 8.96%. The company has an ATR (Average True Range) of 2.38.

Leave a Comment